Biologic predictors of clinical improvement in rituximab-treated refractory myositis Clinical rheumatology and osteoporosis

BMC Musculoskeletal Disorders

Volumn 16, Issue 1, 2015, Pages

  Reed, Ann M ^a   Crowson, Cynthia S ^b   Hein, Molly ^b   De Padilla, Consuelo Lopez ^b   Olazagasti, Jeannette M ^b   Aggarwal, Rohit ^c   Ascherman, Dana P ^d   Levesque, Marc C ^c   Oddis, Chester V ^c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; BIOLOGICAL MARKER; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; PLACEBO; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; CHEMOKINE; CYTOKINE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ASSESSMENT; HUMAN; IMMUNOASSAY; IMMUNOPRECIPITATION; JUVENILE; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); MYOSITIS; OUTCOME ASSESSMENT; REFRACTORY MYOSITIS; SCORING SYSTEM; VISUAL ANALOG SCALE; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; DERMATOMYOSITIS; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; HELPER CELL; IMMUNOLOGY; METABOLISM; MULTICENTER STUDY; POLYMYOSITIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; AUTOANTIBODIES; BIOMARKERS; CHEMOKINES; CYTOKINES; DERMATOMYOSITIS; DOUBLE-BLIND METHOD; HUMANS; POLYMYOSITIS; REMISSION INDUCTION; RITUXIMAB; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES, HELPER-INDUCER; TIME FACTORS; TREATMENT OUTCOME;

EID: 84941919881     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/s12891-015-0710-3     Document Type: Article

References (15)

1. Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65(2):314-24. doi: 10.1002/art.37754.
2. Reed AM, Peterson E, Bilgic H, Ytterberg SR, Amin S, Hein MS, et al. Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course. Arthritis Rheum. 2012;64(12):4078-86. doi: 10.1002/art.34659.
3. Lazarou IN, Guerne PA. Classification, diagnosis, and management of idiopathic inflammatory myopathies. J Rheumatol. 2013;40(5):550-64. doi: 10.3899/jrheum.120682.
4. Zampieri S, Ghirardello A, Iaccarino L, Tarricone E, Gambari PF, Doria A. Anti-Jo-1 antibodies. Autoimmunity. 2005;38(1):73-8. doi: 10.1080/08916930400022640.
5. Ernste FC, Reed AM. Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations. Mayo Clin Proc. 2013;88(1):83-105. doi: 10.1016/j.mayocp.2012.10.017.
6. Nalotto L, Iaccarino L, Zen M, Gatto M, Borella E, Domenighetti M, et al. Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature. Immunol Res. 2013;56(2-3):362-70. doi: 10.1007/s12026-013-8408-9.
7. de Padilla CL, Crowson CS, Hein MS, Khun H, Aggarwal R, Levesque MC, et al. Interferon-Regulated Chemokine and Innate Cytokine Scores Identify Refractory Myositis Patients That Respond Better To Rtuximab Therapy. Arthritis Rheum. 2013;65:S887-S8.
8. Dugan EM, Huber AM, Miller FW, Rider LG. Review of the classification and assessment of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatol Online J. 2009;15(2):2.
9. Reed AM, López De Padilla CM, Crowson CS, Hein MS, Khun H, Aggarwal R et al. Interferon-regulated chemokine and innate cytokine scores identify refractory myositis patients that respond better to rituximab therapy. In press, Sept 2015.
10. Szodoray P, Alex P, Knowlton N, Centola M, Dozmorov I, Csipo I, et al. Idiopathic inflammatory myopathies, signified by distinctive peripheral cytokines, chemokines and the TNF family members B-cell activating factor and a proliferation inducing ligand. Rheumatology. 2010;49(10):1867-77. doi: 10.1093/rheumatology/keq151.
11. Bauer JW, Baechler EC, Petri M, Batliwalla FM, Crawford D, Ortmann WA, et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med. 2006;3(12), e491. doi: 10.1371/journal.pmed.0030491.
12. Fu Q, Chen X, Cui H, Guo Y, Chen J, Shen N, et al. Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients. Arthritis Res Ther. 2008;10(5):R112. doi: 10.1186/ar2510.
13. Rodriguez-Pla A, Patel P, Maecker HT, Rossello-Urgell J, Baldwin N, Bennett L, et al. IFN priming is necessary but not sufficient to turn on a migratory dendritic cell program in lupus monocytes. J Immunol. 2014;192(12):5586-98.
14. Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol. 2011;147(4):391-8. doi: 10.1001/archdermatol.2011.52.
15. Aggarwal R, A. B, Reed A, Ascherman D, Barohn R, Feldman B et al. Clinical and Serologic Predictors of Response in Rituximab-Treated Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis 2013.